Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Celgene (NASDAQ:CELG) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Celgene, and see what CAPS investors are saying about the stock right now.

Celgene facts

 

 

Headquarters (founded)

Summit, N.J. (1980)

Market Cap

$41.8 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$5.5 billion

Management

Chairman/CEO Robert Hugin

CFO Jacqualyn Fouse

Return on Equity (average, past 3 years)

21.9%

Cash / Debt

$3.8 billion / $3.1 billion

Competitors

Johnson & Johnson (NYSE:JNJ)

Pfizer (NYSE:PFE)

Amgen (NASDAQ:AMGN)

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 1,594 members who have rated Celgene believe the stock will outperform the S&P 500 going forward.

Earlier this month, one of those Fools, EpikurFool, succinctly summed up the Celgene bull case for our community:

High expected earnings growth, extremely profitable, still attractive valuation. Core holding in health care business.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.